



UNITED STATES DEPARTMENT OF COMMERCE

Patent and Trademark Office

ASSISTANT SECRETARY AND COMMISSIONER
OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

#12

May 26, 1988

Mr. Ronald Wilson
Office of the Associate Commissioner
for Health Affairs (HFY-20)
Room 11-46
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857

RE: Naftin
FDA Docket # 88E-0183

Dear Mr. Wilson:

Transmitted herewith is a copy of the application for Patent Extension of U.S. Patent No. 4,282,251, issued August 4, 1981. The application was filed on April 28, 1988, under Title II of Public Law 98-417, the Drug Price Competition and Patent Term Restoration Act of 1984.

The patent claims a product and method of using a product that was subject to regulatory review under the Federal Food, Drug and Cosmetic Act. Subject to final review, the subject patent is considered to be eligible for patent term restoration. Thus, a determination of the applicable regulatory review period is necessary. Accordingly, notice a copy of the application are provided pursuant to 35 USC 156(d)(2)(A).

C.E. Van Horn

Charles E. Van Horn
Deputy Solicitor
U.S. Patent and Trademark Office

Gerald D. Sharkin
Patent and Trademark Affairs
Sandoz Pharmaceuticals
59 Route 10
E. Hanover, NJ 07936